Drug intelligence / Profile preview

TuliVax

Development stage: Unknown
Lead developer: The University of New Mexico
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TuliVax is a live-attenuated vaccine candidate developed for the prevention of tularemia, a severe infectious disease caused by the bacterium *Francisella tularensis*. Developed by researchers at the University of New Mexico Health Sciences Center, TuliVax is engineered to be safer and more stable than the historical Live Vaccine Strain (LVS). The vaccine works by stimulating a comprehensive immune response, including both antibody production and T-cell activation, to provide long-lasting protection against various strains of the pathogen, which is recognized as a significant biothreat agent. It is currently undergoing clinical evaluation to assess its safety and immunogenicity in humans.

Brand names: TuliVax

Beyond the preview

Go deeper on TuliVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TuliVax.

Explore the full profile